A meta-opinion: cannabinoids delivered to oral mucosa by a spray for systemic absorption are rather ingested into gastro-intestinal tract: the influences of fed / fasting states

References

• Accessdata.fda.gov [Internet]. Electronic orange book: approved drug products with therapeutic equivalence evaluations. USA: Food and Drug Administration’s; 2018 [cited 2018 Apr 25]. Available from: http://www.accessdata.fda.gov/scripts/cder/ob/
   Google Scholar
• Rathbone MJ, Şenel S, Pather I. Oral mucosal drug delivery and therapy. New York Heidelberg Dordrecht London: Springer; 2015.
   Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007 Aug;4(8):1770–1804.
   PubMed Web of Science ®Google Scholar
• Medicines.org.uk [Internet]. United Kingdom: Datapharm Communications Limited; [cited 2018 Apr 24]. Available from: http://www.medicines.org.uk/emc/product/602/smpc
   Google Scholar
• Gershkovich P, Itin C, Yacovan A, et al. Effect of abdominal surgery on the intestinal absorption of lipophilic drugs: possible role of the lymphatic transport. Transl Res. 2009 Jun;153(6):296–300.
   PubMed Web of Science ®Google Scholar
• Stott CG, White L, Wright S, et al. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013 Apr;69(4):825–834.
   PubMed Web of Science ®Google Scholar
• Millar SA, Stone NL, Yates AS, et al. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365.
   PubMed Web of Science ®Google Scholar
• Stott CG, White L, Wright S, et al. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013 May;69(5):1135–1147.
   PubMed Web of Science ®Google Scholar
• Guy GW, Flint EM. A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of Cannabis Based Medicine Extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT). J Cannabis Ther. 2003;3(3):35–77.
   Google Scholar
• Guy GW, Robson PJ. A phase i, double blind, three-way crossover study to assess the pharmacokinetic profile of Cannabis Based Medicine Extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J Cannabis Ther. 2004;3(4):121–152.
   Google Scholar
• Guy GW, Robson PJ. A phase i, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a Cannabis Based Medicine Extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther. 2004;3(4):79–120.
   Google Scholar
• Karschner EL, Darwin WD, Goodwin RS, et al. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011 Jan;57(1):66–75.
   PubMed Web of Science ®Google Scholar
• Cherniakov I, Izgelov D, Barasch D, et al. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release. 2017;266:1–7.
   PubMed Web of Science ®Google Scholar
• Atsmon J, Cherniakov I, Izgelov D, et al. PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabinoids bioavailability in healthy volunteers. J Pharm Sci. 2018 May;107(5):1423–1429.
   PubMed Web of Science ®Google Scholar
• Oh DA, Parikh N, Khurana V, et al. Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers. Clin Pharmacol. 2017;9:9–17.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology. 2004 Sep;101(3):729–737.
   PubMed Web of Science ®Google Scholar
• Henry JA, Ohashi K, Wadsworth J, et al. Drug recovery following buccal absorption of propranolol. Br J Clin Pharmacol. 1980 Jul;10(1):61–65.
   PubMed Web of Science ®Google Scholar
• Squier CA, Kremer MJ, Bruskin A, et al. Oral mucosal permeability and stability of transforming growth factor beta-3 in vitro. Pharm Res. 1999 Oct;16(10):1557–1563.
   PubMed Web of Science ®Google Scholar
• Serpe L, Jain A, de Macedo CG, et al. Influence of salivary washout on drug delivery to the oral cavity using coated microneedles: an in vitro evaluation. Eur J Pharm Sci. 2016;93:215–223.
   PubMed Web of Science ®Google Scholar
• Lee J, Kellaway IW. Peptide washout and permeability from glyceryl monooleate buccal delivery systems. Drug Dev Ind Pharm. 2002 Oct;28(9):1155–1162.
   PubMed Web of Science ®Google Scholar
• Nicolazzo JA, Reed BL, Finnin BC. Enhanced buccal mucosal retention and reduced buccal permeability of estradiol in the presence of padimate O and A zone: a mechanistic study. J Pharm Sci. 2005 Apr;94(4):873–882.
   PubMed Web of Science ®Google Scholar
• Nicolazzo JA, Reed BL, Finnin BC. Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide. J Control Release. 2005 Jul;105(3):240–248.
   PubMed Web of Science ®Google Scholar
• Schürmann W, Turner P. A membrane model of the human oral mucosa as derived from buccal absorption performance and physicochemical properties of the beta-blocking drugs atenolol and propranolol. J Pharm Pharmacol. 1978 Mar;30(3):137–147.
   PubMed Web of Science ®Google Scholar